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i g h l i g h t s
We have developed a novel poly -caprolactone peripheral nerve conduit.
Our experimental in vivo model compares PCL nerve conduit repair with autograft.
Long term outcomes display comparable re-innervation of end organ muscle and skin.
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a b s t r a c t
The gold standard in surgical management of a peripheral nerve gap is currently autologous nerve
grafting. This confers patient morbidity and increases surgical time therefore innovative experimen-
tal strategies towards engineering a synthetic nerve conduit are welcome. We have developed a novel
synthetic conduit made of poly -caprolactone (PCL) that has demonstrated promising peripheral nerve
regeneration in short-term studies. This material has been engineered to permit translation into clinical
practice and here we demonstrate that histological outcomes in a long-term in vivo experiment are com-
parable with that of autologous nerve grafting. A 1 cm nerve gap in a rat sciatic nerve injury model waserve conduit
eripheral nerve
oly -caprolactone
repaired with a PCL nerve conduit or an autologous nerve graft. At 18 weeks post surgical repair, there
was a similar volume of regenerating axons within the nerve autograft and PCL conduit repair groups,
and similar numbers ofmyelinated axons in the distal stump of both groups. Furthermore, therewas evi-
dence of comparable re-innervation of end organmuscle and skinwith the only signiﬁcant difference the
lower wet weight of the muscle from the PCL conduit nerve repair group. This study stimulates further
of th
2013work on the potential use
©
. Introduction
The management of peripheral nerve gap following injury is a
urgical challenge. The gold standard in clinical practice for surgi-
al repair of a peripheral nerve gap remains an autologous nerve
raft [2,10]. However, the use of autologous nerve graft confers
orbidity such as loss of sensation and scarring at the donor site,
an be time-consuming and a technical challenge for the surgeon,
s a ﬁnite resource, and nerve size mismatch has to be overcome
y using multiple lengths of nerve graft within the defect. The
unctional recovery of this reconstruction remains deﬁcient and
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these injuries can have a profound and permanent impact on the
patient and their ability to perform activities of daily living as
well as preventing return to work [8,14]. Poor outcomes may be
a direct consequence of slow, insufﬁcient and misdirected axonal
outgrowth at the site of injury [1,4]. Whilst innovative experimen-
tal strategies have been employed to engineer a synthetic nerve
conduit to bridge the defect, nothing yet has proven good enough
to be used routinely in clinical practice [3,6,20]. Conduits approved
for current clinical use include collagen and synthetic polyester-
based materials; however, their use has been limited due to the
lack of good clinical data, relative expense and inability to bridge
large nerve gaps [9].
Recently, the synthetic biomaterial poly -caprolactone (PCL)
has demonstrated great promise as a novel nerve conduit which
is ultrathin with a pitted structure formed by solvent casting on a
Open access under CC BY license.glass slide and sealed with a controlled heating method [13,15].
This manufacturing process is low cost, reproducible, allows
easy sterilisation with unique properties allowing ﬂexibility and
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any features that would suggest an ideal nerve conduit; in par-
icular it is biodegradable, non-toxic, non-immunogenic, and may
ncorporate supportive cells into its structure. In short-term stud-
es, excellent nerve regeneration has been demonstrated with the
se of PCL conduit to bridge a 1 cm nerve gap such that a large vol-
me of axons consistently bridged the 1 cm gap at only 2 weeks
ost-injury [16]. In order to understand the potential for clinical
ranslation of this nerve conduit, it is crucial to demonstrate long-
ermoutcomes such as re-innervationof endorgan skin andmuscle
nd compare this to the current clinical gold-standard. This study
ought to test the long-term regeneration of an in vivo peripheral
erve injury when repaired with a PCL nerve conduit as compared
o an autologous graft across a 1 cm nerve gap in a rat sciatic nerve
njury model.
. Materials and methods
.1. Experimental design
We compared experimental peripheral nerve repair of a 1 cm
ap using empty PCL conduit versus autologous nerve graft. Out-
ome measures compared were axonal counts and myelination in
he conduit or autograft and in the distal stump; end organ muscle
bre size and weights; and end organ skin re-innervation.
.2. Preparation of PCL conduits
Poly-caprolactone (PCL), conduitswerepreparedaspreviously
escribed [15]. Brieﬂy, 3% (w/v) of PCL (Sigma Aldrich, US) was dis-
olved in dichloromethane (Fisher Scientiﬁc, UK) and spread evenly
n degreased borosilicate glass cover slip. Following complete sol-
ent evaporation, the ﬁlms were treated in 10N NaOH for 1h with
entle shaking and washed in distilled H2O. Films were cut into
ectangular sheets and rolled around a 16G intravenous cannula
Abbocath®, Abbott Ireland, Republic of Ireland), which standard-
sed the internal diameter of the conduits at 1.6mm, more than
.5 times the diameter of rat sciatic nerve, thus allowing space for
ost-injury swelling. Conduits were sealed by controlled heating
hile still mounted on the cannula and then sterilised using UV
adiation.
.3. Surgical procedures and groups
The animal care and experimental procedures were performed
n accordance with the terms of the United Kingdom Animals
Scientiﬁc Procedures) Act 1986 and the number of animals
sed was kept to a minimum. Surgical procedures were per-
ormed under isoﬂuorane general anaesthesia on young adultmale
prague–Dawley rats (180–220g). All animals underwent sciatic
erve transection and a 10mm nerve gap was created at the level
f the mid-femur. In the autologous nerve graft group (n=5) under
icroscope vision the resected 10mmof sciatic nervewas reversed
uch that the distal end was sutured to the proximal nerve stump
nd the proximal end to the distal stump; in the PCL conduit repair
roup (n=5), the proximal and distal nerve stumps of the tran-
ected nerve were secured 2mm within the PCL conduit using 4
nterrupted 9-0 Ethilon epineurial sutures (Ethicon, US). The con-
uit had been cut to 14mm length in order to maintain a 10mm
ap between the nerve stumps. The wound was closed in layers
nd post-operative analgesia was given as 4g buprenorphine
ntramuscularly. The animals were caged in a temperature and
umidity controlled room with a 12-h light/dark cycle, and food
nd water provided immediately. After 18 weeks survival, animals
ere deeply anaesthetisedwith isoﬂuorane and perfused transcar-
iallywith 0.9% heparinised saline (0.9% NaCl, 50 units/ml heparin)ters 544 (2013) 125–130
followed by 4% paraformaldehyde in 0.1M phosphate buffer solu-
tion (PBS). The sciatic nerves including PCL conduit were harvested
and post-ﬁxed in 4% paraformaldehyde before being frozen in
OCT embedding medium (VWR, UK) and stored at −40 ◦C. For
axon counts, 2–3mm long sciatic nerve specimens were excised
at 3mm distance from the proximal and distal nerve graft/conduit
interfaces. These nerve segments were ﬁxed in 3% glutaraldehyde,
post-ﬁxed in1%osmiumtetroxide (OsO4) in0.1Mcacodylatebuffer
(pH7.4), dehydrated in acetone and embedded in Vestopal. Both
ipsilateral and contralateral medial gastrocnemius muscles were
weighed and then frozen in OCT using isopentane cooled with liq-
uid nitrogen and foot pad skinwas post-ﬁxed in Zamboni’s solution
before being frozen in OCT embedding medium (VWR, UK) and
stored at −40 ◦C.
2.4. Axon counts
Semi-thin transverse sections of proximal and distal nerve
segments were cut on a 2128 Ultratome (LKB, Sweden) and coun-
terstained with Toluidine Blue. Myelinated axons in the these
segments were counted at 1000× ﬁnal magniﬁcation using the
fractionator probe in Stereo InvestigatorTM 6 software (Micro-
BrightField, Inc., USA).
2.5. Axonal regeneration
Random longitudinal nerve sections were cut with a thickness
of 14m and collected onto glass slides coated with Vectabond
(Vector, Peterborough, UK). The sections were permeabilised in
0.2% (v/v) Triton-X in PBS and washed twice in PBS for 5min. They
were then blockedwith normal goat serum (Sigma, UK; 1:100 dilu-
tion) and the primary antibody (protein gene product 9.5, PGP 9.5,
Dako, UK; 1:1000) was applied overnight. The following day, the
sections were washed three times in PBS and a ﬂuorescein goat
anti-rabbit conjugated secondary antibody (Vector Laboratories,
UK; 1:100) was applied. The sections were ﬁnally washed carefully
in PBS and mounted on glass slides with Vectashield. After stain-
ing, each section was examined by ﬂuorescence microscopy using
a 20× objective. Measurements were carried out at 5mm from the
proximal stump and imageswere captured using anOlympus BX60
invertedﬂuorescencemicroscope andamonochromecamera (Evo-
lutionQEi,MediaCybernetics, Bethesda, USA). The immunostaining
area was then quantiﬁed using Image Pro Plus Imaging Software
(Media Cybernetics). Images were converted into grayscale and
thresholded. The immunostaining area was ﬁnally evaluated auto-
matically by the software and expressed asm2. The ﬁnal staining
area was expressed as the ratio between the staining area and the
total frame area.
2.6. Muscle analysis
Sixteen micron transverse sections of gastrocnemius muscles
from the contra-lateral and operated sides were cut on a cryostat
and samples were then ﬁxed in 4% (w/v) paraformaldehyde for
15min at room temperature, washed brieﬂy in phosphate buffered
saline (PBS) and permeabilised in 0.1% (v/v) Triton X-100 in PBS for
30min. Samples were blocked with normal serum and then incu-
bated with monoclonal primary antibodies raised against fast and
slowmyosinheavychainprotein (NCL-MHCfandNCL-MHCs,Novo-
castra, Peterborough, UK; both 1:20) for 2h at room temperature.
Each slidewas also co-incubatedwith rabbit anti-laminin antibody
(Sigma, Poole, UK; 1:200). After rinsing inphosphate-buffered solu-
tion, secondary goat anti-rabbit and goat anti-mouse antibodies
Alexa Fluor 488 and Alexa Fluor 568 (Invitrogen, The Netherlands;
1:100) were applied for 1h at room temperature in the dark.
The slides were cover-slipped with Prolong anti-fade mounting
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Fig. 1. Myelination morphology is very similar between the autograft and PCL conduit nerve repair groups (A, scale =20m). Furthermore, the axonal regeneration seen
within the autograft and PCL nerve conduit by PGP immunohistochemical staining was similar (B, scale =50m). Myelinated axon counts demonstrated similar numbers in
the distal stumps of both groups 7729±1308 and 6414±1544 axons in autograft and conduit respectively (C). The percentage of regenerating axons within the autograft
(48±2%) and PCL nerve conduit (52±3%) were not signiﬁcantly different (D).
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Fig. 2. Immunohistochemistry of fast and slow muscle ﬁbres from the medial gastrocnemius muscle demonstrating similar sizes of muscle ﬁbre (A, scale =50m). The area















sutograft and the PCL nerve conduit repair groups. Fast muscle ﬁbre area was 84.0±
rea was 71.2±7.0% in the autograft group and 76.5±7.8% in the PCL conduit group
CL conduit group; slow muscle ﬁbre diameter was 74.3±3.6% in the autograft gro
edium containing 4′,6-diamidino-2-phenylindole (DAPI; Invitro-
en). Morphometric analysis of muscle sections was performed
n a blind manner using randomly assigned codes as previously
escribed [12]. Five random ﬁelds were chosen (using the 16×
icroscope objective) and images for the immunolocalisation of
ach myosin heavy chain type plus that for laminin were captured
sing the appropriate emission ﬁlters, and combined to provide
ual-labelled images. Each image contained at least 25 individual
uscle ﬁbres for analysis. Image-Pro Plus software was calibrated
o calculate the mean area and diameter (in m) for each muscle.
he injured sidewas expressed relative to the contra-lateral control
ide and the relative mean%± SEM calculated for each group.in the autograft group and 72.6±7.0% in the PCL conduit group; slow muscle ﬁbre
muscle ﬁbre diameter was 84.8±1.6% in the autograft group and 77.8±5.7% in the
d 78.0±4.7% in the PCL conduit group.
2.7. Skin re-innervation
Systematic random samples of 15m cryosections from ipsi-
lateral foot pad skin were collected onto glass slides coated with
Vectabond. Sections were permeabilised in 0.2% Triton-X (BDH
Laboratory Supplies, Bristol, UK), and stained by indirect immuno-
histochemistry using primary antisera against polyclonal rabbit
antisera for protein gene product 9.5 (PGP 9.5; 1:1000) and poly-
clonal rabbit calcitonin gene-related peptide (CGRP; Sigma, UK;
1:1000). PGP antibodies identify all nerve ﬁbre types whilst CGRP
antibodies are speciﬁc for C and A  sensory ﬁbres. Staining was
visualisedusingaﬂuorescein isothiocyanate-conjugatedsecondary



















tig. 3. PGP and CGRP immunohistochemistry demonstrating nerve regeneration in
r PCL conduit (A). PGP immunostaining (B) was present in 0.29±0.07% of the skin
roup. CGRP immunostaining (C) was present in 0.16±0.03% of the skin area in the
ntibody (conjugatedgoat anti-rabbit serum;1:100).After staining,
ach sectionwasexaminedbyﬂuorescencemicroscopyusinga20×
bjective. For each antibody, a random sample of six visual ﬁelds,
ncluding epidermis and dermis was captured for analysis using
n Olympus BX60 inverted ﬂuorescence microscope and images
cquired using a monochrome camera. The immunostaining area
n each captured image was quantiﬁed by image analysis using
mage-Pro Plus Imaging software as previously described [7]. First
he colour immunoﬂuorescent imagewas converted intogreyscale;
hen the epidermis and dermis was outlined by tracing its mar-
in. An intensity threshold was applied to differentiate bright
mmunostaining from any low-level background autoﬂuorescence,
nd the immunostaining area was calculated automatically.
.8. StatisticsGraphPad Prism 4© software (GraphPad Software, San Diego,
A, USA) was used to calculate statistics. An unpaired student t-
est was used to compare the two experimental groups. All datarmis of ipsilateral foot pad skin 18 weeks after sciatic nerve repair with autograft
n the autograft group compared to 0.35±0.05% of the skin area in the PCL conduit
raft group compared to 0.11±0.02% in the PCL conduit group.
was expressed as mean± SEM. A value of P<0.05 was considered
to be statistically signiﬁcant.
3. Results
No adverse events were encountered in the use of the PCL con-
duit in the 18-week survival period and there was no evidence of
conduit degradation at this time point.
3.1. Axon counts
Specimens of the distal nerve were harvested 3mm from the
graft/conduit nerve interface and contained numerous myelinated
nerve ﬁbres (Fig. 1). There were not any marked differences in
appearance and distribution of myelinated ﬁbres between the
autograft and PCL conduit experimental groups (Fig. 1A) and quan-
titative analysis demonstrated that similar numbers of axons were
found in the distal stumps of both groups (Fig. 1C). Proximal stump
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In order to measure and compare the extent of axonal regen-
ration within the nerve repaired with conduit or autograft, the
rea highlighted by PGP immunohistochemical staining (Fig. 1B)
as expressed as a proportion of the area within the conduit
r autograft (Fig. 1D). This demonstrated that there was no sig-
iﬁcant difference between the volumes of regenerating axons
ithin the nerve repairedwith conduit and the nerve repairedwith
utograft.
.2. Muscle ﬁbre size and weights
The area and diameter of both fast and slow muscle ﬁbre types
as measured after immunohistochemical staining of the medial
astrocnemius muscle (Fig. 2). There were no statistically signif-
cant differences between the autograft and the PCL groups for
uscle ﬁbre area or diameter. Thewetmuscleweight of themedial
astrocnemius muscle supplied by the nerve repaired with auto-
raft was signiﬁcantly heavier than the wet weight of medial
astrocnemius muscle supplied by the nerve repaired with PCL
erve conduit (60.24±2.6% and 48.58±3.1% of contralateral sides
espectively, P<0.05).
.3. Skin re-innervation
Skin re-innervation was measured by CGRP and PGP immuno-
istochemical staining of the ipsilateral footpad skin (Fig. 3). There
as nerve regeneration into the dermis of all sections examined.
here were no statistically signiﬁcant differences between the
utograft and the PCL groups for the immunostaining area of CGRP
r PGP.
. Discussion
Autologous nerve grafting remains the clinical gold standard for
epair of a nerve gap; however, much promising work has been
eported in the development of synthetic nerve conduits to fulﬁl
his role. This study provides evidence of comparable long-term
istological outcomes in in vivo nerve gap repair with autograft or
novel PCL nerve conduit; thereby stimulating furtherwork on the
otential use of this synthetic biodegradable PCL nerve conduit in
he clinical setting. In our previous in vivo study of this nerve con-
uit, we demonstrated that a large volume of axons consistently
ridged a 1 cm rat sciatic nerve gap at only 2 weeks post-injury
16]. At 18weeks therewas a similar volume of regenerating axons
ithin the nerve autograft and PCL conduit repair groups, and simi-
ar numbers ofmyelinated axons in the distal stumpof both groups.
urthermore, there was evidence of comparable re-innervation of
nd organ muscle and skin with the only signiﬁcant difference the
ower wet weight of the muscle from the PCL conduit nerve repair
roup. Given that there is a similar muscle ﬁbre size and number
f myelinated axons between the two groups, the mechanism of
different muscle weight is unclear; however, the long survival
eriod in this study may conceal differences in aspects of regener-
tion that could have been detected at earlier time points, andmay
e more critical in a human model [19]. Regeneration is slower
nd over much longer distances in humans than in rats, which
onfers increased susceptibility to target organ atrophy. However,
he results of the PCL conduit are favourable when compared with
ecent studies examining collagen and ﬁbrin nerve conduits versus
utologous nerve grafting [11,18]. After 18 weeks survival, there
erenoadverse incidentsand thePCLconduit remained intactwith
o evidence of degradation. This indicates that the conduit could
rovide support for axonal regeneration over longer distances and
onger periods of time. This is useful in a human model whereby
[ters 544 (2013) 125–130
nerve conduits may need to provide support for many months of
nerve guidance.
It is clear that further experimental studies and innovation will
be required before a bioengineered conduit demonstrates superi-
ority to an autologous nerve graft. This may be realised with the
advent of stem cell integration within conduits and the manipu-
lation of the conduit lumen to bear physical or chemical cues in
order to aid axonal regeneration [5,13,17]. Features such as thiswill
attempt to recreate the cellular andmolecular ‘regenerative mileu’
of an autologous nerve graft within a biomaterial nerve conduit.
Acknowledgements
A.R. is supported by the National Institute for Health Research,
Academy of Medical Sciences and the British Society for Surgery of
theHand.Wealsoacknowledge support fromtheSwedishResearch
Council and the Newby Trust.
References
[1] R. Birch, Nerve repair, in: S.W.Wolfe, R.N. Hotchkiss, W.C. Pederson, S.H. Kozin
(Eds.), Green’s Operative Hand Surgery 6th Ed, Elsevier Science, Amsterdam,
2011, pp. 1035–1074.
[2] R. Birch, G. Bonney, C. Wynn Parry, Surgical Disorders of the Peripheral Nerves,
Churchill Livingston, London, 1998.
[3] T. Carlstedt, An overture to basic science aspects of nerve injuries, J. Hand Surg.
Eur. 36 (2011) 726–729.
[4] L. Dahlin, The biology of nerve injury and repair, J. Am. Soc. Surg. Hand 4 (2004)
143–155.
[5] A.C. de Luca, G. Terenghi, S. Downes, Chemical surface modiﬁcation of poly-
epsilon-caprolactone improves Schwann cell proliferation for peripheral nerve
repair, J. Tissue Eng. Regen. Med. (2012), http://dx.doi.org/10.1002/term.1509
(epub ahead of print).
[6] G.R. Evans, Challenges to nerve regeneration, Semin. Surg. Oncol. 19 (2000)
312–318.
[7] A.M. Hart, A.D. Wilson, C. Montovani, C. Smith, M. Johnson, G. Terenghi, M.
Youle, Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated
antiretroviral toxic neuropathy, AIDS 18 (2004) 1549–1560.
[8] G. Lundborg, A 25-year perspective of peripheral nerve surgery: evolving neu-
roscientiﬁc concepts and clinical signiﬁcance, J. Hand Surg. Am. 25 (2000)
391–414.
[9] M.F. Meek, J.H. Coert, US Food and Drug Administration/Conformit Europe-
Approved Absorbable Nerve Conduits for clinical repair of peripheral and
cranial nerves, Ann. Plast. Surg. 60 (2008) 466–472.
10] H.Millesi, Bridging defects: autologous nerve grafts, ActaNeurochir. Suppl. 100
(2007) 37–38.
11] J. Pettersson, D. Kalbermatten, A. McGrath, L.N. Novikova, Biodegradable ﬁbrin
conduit promotes long-term regeneration after peripheral nerve injury in adult
rats, J Plast. Reconstr. Aesthet. Surg. 63 (2010) 1893–1899.
12] J. Pettersson, A.McGrath, D.F. Kalbermatten, L.N. Novikova,M.Wiberg, P.J. King-
ham, L.N. Novikov, Muscle recovery after repair of short and long peripheral
nerve gaps using ﬁbrin conduits, Neurosci. Lett. 500 (2011) 41–46.
13] A.J. Reid, M. Sun, M.Wiberg, S. Downes, G. Terenghi, P.J. Kingham, Nerve repair
with adipose-derived stem cells protects dorsal root ganglia neurons from
apoptosis, Neuroscience 199 (2011) 515–522.
14] H.E. Rosberg, K.S. Carlsson, S. Hojgard, B. Lindgren, G. Lundborg, L.B. Dahlin,
Injury to the humanmedian and ulnar nerves in the forearm—analysis of costs
for treatment and rehabilitation of 69 patients in southern Sweden, J. Hand
Surg. Br. 30 (2005) 35–39.
15] M. Sun, S. Downes, Physicochemical characterisation of novel ultra-thin
biodegradable scaffolds for peripheral nerve repair, J. Mater. Sci. Mater. Med.
20 (2009) 1181–1192.
16] M. Sun, P.J. Kingham, A.J. Reid, S.J. Armstrong, G. Terenghi, S. Downes, In vitro
and in vivo testing of novel ultrathin PCL and PCL/PLA blend ﬁlms as peripheral
nerve conduit, J. Biomed. Mater. Res. A 93 (2010) 1470–1481.
17] M. Sun, M.McGowan, P.J. Kingham, G. Terenghi, S. Downes, Novel thin-walled
nerve conduit with microgrooved surface patterns for enhanced peripheral
nerve repair, J. Mater. Sci. Mater. Med. 21 (2010) 2765–2774.
18] T.Waitayawinyu,D.M. Parisi, B.Miller, S. Luria,H.J.Morton, S.H. Chin, T.E. Trum-
ble, A comparison of polyglycolic acid versus type 1 collagen bioabsorbable
nerve conduits in a rat model: an alternative to autografting, J. Hand Surg. Am.
32 (2007) 1521–1529.
19] E.L. Whitlock, S.H. Tuffaha, J.P. Luciano, Y. Yan, D.A. Hunter, C.K. Magill, A.M.
Moore, A.Y. Tong, S.E. Mackinnon, G.H. Borschel, Processed allografts and type
I collagen conduits for repair of peripheral nerve gaps, Muscle Nerve 39 (2009)
787–799.
20] M. Wiberg, G. Terenghi, Will it be possible to produce peripheral nerves? Surg.
Technol. Int. 11 (2003) 303–310.
